AN2 Therapeutics, Inc. (ANTX) Stock Score, Valuation & Financial Research

AN2 Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ANTX

AN2 Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 5.32. These figures are a research snapshot, not a buy or sell recommendation.

What AN2 Therapeutics, Inc. does

AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

AN2 Therapeutics is a clinical-stage biopharmaceutical company that generates no product revenue. It funds its research and development activities primarily through equity financing, capital raises, and non-dilutive grant agreements while incurring significant operating expenses to advance its boron-based small-molecule drug candidates.

Products and services

  • The company is developing a pipeline of boron-based small-molecule therapeutics, including epetraborole for the treatment of non-tuberculous mycobacterial (NTM) lung disease and melioidosis, as well as AN2-502998 for Chagas disease.

Customer types

Clinical research organizations and medical institutions.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of its drug candidates for preclinical and clinical studies; specific supplier names are unnamed. Source

Business strengths to evaluate

  • Proprietary boron chemistry platform Source

Business risks and research considerations

  • History of operating losses and accumulated deficit Source
  • Dependence on third-party contract manufacturers Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ANTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 5.32
Market capitalization:
191.61M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -36.28M
Free cash flow:
USD -29.83M
Cash:
USD 44.32M
Total debt:
USD 0.00
EPS:
USD -1.07

What stands out

  • Free cash flow is USD -29.83M, negative for the stored period.
  • The balance sheet shows USD 44.32M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 44.32M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ANTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ANTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ANTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ANTX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ANTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research ANTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.